---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-084317"
form_type: "8-K"
ticker: "NKTR"
cik: "0000906709"
company_name: "NEKTAR THERAPEUTICS"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T18:37:53.469422+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nektar reports Q3 net loss $45.8M, cash $372.7M; Phase 2b atopic derm study initiated

## Summary
- Net loss $45.8M ($0.24/shr) vs $59.0M y/y; non-GAAP loss $35.7M ($0.19/shr).
- Revenue $24.1M, slightly up from $23.6M y/y; cash $372.7M, down from $505.0M at year-end.
- Initiated Phase 2b study of rezpegaldesleukin in atopic dermatitis (Oct 2023); Phase 2b alopecia areata to start early 2024.
- Clinical collaboration with CBMG to evaluate NKTR-255 in combination with TIL therapy in NSCLC.
- R&D expense reduced to $24.1M (Q3) due to wind-down of bempegaldesleukin program.

## SEC filing metadata
- accession: 0001213900-23-084317
- form_type: 8-K
- ticker: NKTR
- cik: 0000906709
- company_name: NEKTAR THERAPEUTICS
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/0001213900-23-084317-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/ea187824-8k_nektarther.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-084317
- JSON: https://secwatch.observer/filing/0001213900-23-084317.json
- Plain text: https://secwatch.observer/filing/0001213900-23-084317.txt

## Key facts
- Earnings Releases
  NEKTAR THERAPEUTICS reported the third quarter ended September 30, 2023 results: revenue $24.1 million, net income Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share, EPS $0.24 basic and diluted loss per share.
  - Period: the third quarter ended September 30, 2023
  - Revenue: $24.1 million
  - Net income: Net loss for the third quarter of 2023 was $45.8 million or $0.24 basic and diluted loss per share
  - EPS: $0.24 basic and diluted loss per share
  - Result: reported results
  source text: least $320 million in cash and investments which provides us with a cash runway into the middle of 2026.” Summary of Financial Results Revenue in the third quarter of 2023 was $24.1 million as compared to $23.6 million in the third quarter of 2022. Revenue for the first nine months of 2023 was $66.2 million as compared to $70.0 million in the first nine months of
  evidence_url: https://www.sec.gov/Archives/edgar/data/906709/000121390023084317/0001213900-23-084317-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.